This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.
Skin & pigmentation: what the human evidence shows
Each peptide is sorted by the strongest kind of human study among its profile’s selected studies, and the row shows what that study found and who was studied. A higher tier means stronger evidence exists, not that the peptide works for skin & pigmentation: the best trial may be small, negative or about a different condition. No doses.
Peptide
Strongest human evidence in our sources
FDA
Human safety data
FDA-approved medicine (1)Approved for the specific uses on its label, which may not be this goal.
Afamelanotide implants in erythropoietic protoporphyria (2015) · Human randomized trials Pain-free sun exposure was longer with afamelanotide in both trials, and quality-of-life measures improved. Reported median exposure values differed considerably between the two study settings. Limitation: These findings are specific to EPP and the tested implants. They do not establish a safe cosmetic tanning regimen or interchangeability with Melanotan II. Studied: 74 participants in the European trial and 94 in the US trial, all with EPP.
FDA-approved
FDA label
Randomized human trials (4)At least one randomized or placebo-controlled trial, which may be small, negative or about another condition.
Argireline for peri-orbital wrinkles (2013) · Human randomized cosmetic trial The publication reported improved wrinkle grading and skin-roughness measurements with the Argireline formulation. Limitation: Short cosmetic follow-up cannot establish durable effects, all-serum equivalence, or equivalence to botulinum toxin injection. Studied: 60 Chinese participants with peri-orbital wrinkles.
Laser-resurfacing skin study (2006) · Small human randomized trial (topical) No significant difference in redness resolution, wrinkles or overall skin quality on objective measures; patients using GHK-Cu reported higher satisfaction on a questionnaire. Limitation: Thirteen people, a cosmetic skin product and a mostly negative objective result. It says nothing about injected GHK-Cu, which is what FDA flagged. Studied: 13 adults who completed the study after CO2 laser resurfacing around the mouth.
Pal-KTTKS split-face trial (2005) · Human randomized cosmetic trial Wrinkle and fine-line grading favored the peptide-containing formulation, which was reported as well tolerated. Limitation: The result applies to this formulation and cosmetic follow-up. It does not establish an injection treatment or verify every product using the Matrixyl name. Studied: 93 women aged 35–55.
Melanotan II · organic erectile dysfunction (2000) · Human randomized trial Erections followed 12 of 19 Melanotan II injections compared with 1 of 21 placebo injections. Severe nausea followed 4 of 19 Melanotan II injections. Limitation: Very small and short. Side effects were common, and the drug was not approved. Studied: 10 men with organic erectile dysfunction.
Not approved
Trials only
Small or uncontrolled human studies (1)Human reports without randomization, such as pilots, case series or open-label studies.
Combination hyaluronic-acid patch for eye wrinkles (2024) · Human comparative cosmetic study Several wrinkle measurements favored the active combination patch. No adverse events were reported during the short follow-up. Limitation: This comparison cannot isolate SNAP-8, establish long-term effects, or validate every serum containing acetyl octapeptide-3. Studied: 24 healthy volunteers.
Not approved
Very limited
Animal and lab studies only (3)No human study in our sources.
Selected studies, not a systematic review. Approval belongs to a specific product and use. Side-by-side comparisons: GHK-Cu vs AHK-Cu (all comparisons).
Afamelanotide is an alpha-MSH analogue investigated for photoprotection in erythropoietic protoporphyria (EPP). Melanotan I is a research name associated with this molecule; an implant trial does not verify a retail research vial.
AHK-Cu is a copper complex of the tripeptide alanine-histidine-lysine. It is related to GHK-Cu but is a different molecule. Its featured evidence uses donated human hair follicles and cultured cells, not people using a product.
Argireline is an acetylated hexapeptide used in cosmetics. A short placebo-controlled trial studied a topical formulation for wrinkles around the eyes.
GHK-Cu combines a short peptide with copper. It is discussed in topical skin care and tissue-remodeling research, which should be separated from injection claims.
The Matrixyl ingredient covered here is palmitoylated KTTKS, also known as palmitoyl pentapeptide-4. A split-face study compared a moisturizer containing this ingredient with its base formulation.
Melanotan II is a synthetic, ring-shaped analog of alpha-MSH that darkens skin by acting on melanocortin receptors throughout the body. About 23 people were given it in small studies from 1996 to 2000; it was never approved, and case reports link it to changing moles, melanoma and other serious harms. It is a different drug from the approved afamelanotide (Scenesse) and bremelanotide (Vyleesi).
PTD-DBM is an experimental motif peptide investigated in Wnt-associated hair-follicle biology. The featured work included human tissue and cells alongside mouse experiments, rather than a controlled human hair-regrowth trial.
SNAP-8 is an acetylated octapeptide used in cosmetics. The featured study tested a combination patch with several active ingredients, so its result does not isolate the effect of SNAP-8.
We check sellers’ lab reports with the testing labs themselves.
So far 89 of the 105 lab reports we looked up matched the testing lab’s own record, and 12 did not.
A free account shows which sellers, report by report, plus daily prices, deals, Ask PepsRadar and alerts. If you want it, the PepsRadar Weekly brings new research and FDA news once a week. No dosing advice.